Bacterial abundance in L2 larvae collected from larval flasks inoculated with decreasing quantities of glycerol stock (bacteria source). by Margaret V. Becker (21387776)

Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

“…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”

Highest V1V2 IgG3 binding magnitude observed among ALVAC-HIV/AIDSVAX B/E only recipients. by LaTonya D. Williams (3140490)

Subjects:

Is the only transcript decreasing in cells following tunicamycin treatment by Maho Niwa (7152)

Chemotherapy decreases cell proliferation in the adult mouse CNS by Joerg Dietrich (35101)

<i>csrnp1a</i> knockdown decreases the number of blood cells in circulation. by Jaime Espina (106906)

“…(I) qPCR with primers located in exon 2 and 3 of 24 hpf control embryos (C) and splicing morphants injected with two concentrations, 2,5 and 5 ng per embryo, showing the relative expression of <i>csrnp1a</i> message, which decreases significantly in a dose-dependent manner (t student p<0,01).…”

NS4B decreases TRIF protein level. by Yisha Liang (5244368)

Decrease in parasite biomass and IRBC accumulation in organs in infected Rag2^−/− mice. by Carla Claser (185910)

HCV infection decreases MIN6 cell viability. by Qian Wang (32718)

Procedures of sampling and measurements. by Xuegang Mao (599968)

Subjects:

Enclosures and photos from video records. by André V. Rubio (4594702)

siRNA treatment decreases ADAMTS-1 nuclear pattern in MDA-MB-231 cells. by Suély V. Silva (3233223)

“…(D-E) Aggrecan Western blot after digestion. Lane 1: Aggrecan from bovine articular cartilage (300 nM); Lane 2: Aggrecan from bovine articular cartilage (300 nM) incubated with 30 μg of MDA-MB-231 nuclear fraction; Lane 3: 30 μg of MDA-MB-231 nuclear fraction. …”

A brief course of RAP treatment decreases markers of proliferation and increases markers of differentiation. by Karin M. Hardiman (555189)

“…<p><i>CDX2P-CreER^T2 Apc^fl/fl</i> mice were injected with TAM and monitored until polyposis was seen endoscopically, then the mice were treated with vehicle or RAP at 3 mg/kg concentration for periods of one, three, or five days (N = 5 per timepoint). …”

GO treatment decreased SR-B1 levels. by Claudia Sticozzi (329024)

Decreased health-related quality of life in angiodysplasia patients: A cross-sectional cohort by Karina V. Grooteman (4050388)

Sequence comparisons of <i>dim2</i> alleles in <i>Z</i>. by Mareike Möller (5548745)

Subjects:

Dcp1a protein levels are decreased by KapB expression and Torin treatment. by Carolyn-Ann Robinson (13297009)

Oxytocin decreases postsynaptic CeA spontaneous GABAergic transmission and blocks presynaptic alcohol effects. by Brendan J. Tunstall (6593357)

“…^#Significant difference between groups (<i>p</i> < 0.05). Amp, amplitude; CeA, central nucleus of the amygdala; EtOH, ethanol; Freq, frequency; mIPSC, miniature inhibitory postsynaptic current; OT, oxytocin; OTA, desGly-NH2-d(CH2)5[D-Tyr2,Thr4]OVT; sIPSC, spontaneous inhibitory postsynaptic current; TTX, tetrodotoxin.…”

Pharmacological Mechanism of the Non-hallucinogenic 5‑HT_2A Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”

Pharmacological Mechanism of the Non-hallucinogenic 5‑HT_2A Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”